Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making

Abstract

BackgroundThe objective of this study is to investigate the role and experience of early stage non-small cell lung cancer (NSCLC) patient in decision making process concerning treatment selection in the current clinical practice.MethodsStage I-II NSCLC patients (surgery 55 patients, SBRT 29 patients, median age 68) were included in this prospective study and completed a questionnaire that explored: (1) perceived patient knowledge of the advantages and disadvantages of the treatment options, (2) experience with current clinical decision making, and (3) the information that the patient reported to have received from their treating physician. This was assessed by multiple-choice, 1–5 Likert Scale, and open questions. The Decisional Conflict Scale was used to assess the decisional conflict. Health related quality of life (HRQoL) was measured with SF-36 questionnaire.ResultsIn 19% of patients, there was self-reported perceived lack of knowledge about the advantages and disadvantages of the treatment options. Seventy-four percent of patients felt that they were sufficiently involved in decision-making by their physician, and 81% found it important to be involved in decision making. Forty percent experienced decisional conflict, and one-in-five patients to such an extent that it made them feel unsure about the decision. Subscores with regard to feeling uninformed and on uncertainty, contributed the most to decisional conflict, as 36% felt uninformed and 17% of patients were not satisfied with their decision. HRQoL was not influenced by patient experience with decision-making or patient preferences for shared decision making.ConclusionsDutch early-stage NSCLC patients find it important to be involved in treatment decision making. Yet a substantial proportion experiences decisional conflict and feels uninformed. Better patient information and/or involvement in treatment-decision-making is needed in order to improve patient knowledge and hopefully reduce decisional conflict.Electronic supplementary materialThe online version of this article (10.1186/s12885-018-3986-5) contains supplementary material, which is available to authorized users.

The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life

“…The third is that as patients live beyond their original prognosis, they are able to turn their attention to other health concerns, and there is limited research and standardized practices around treatment for health issues concomitant to stage IV NSCLC. Recent research finds that a significant percentage of patients treated for NSCLC experience decisional conflict around their therapy and feel uninformed [68]. While our research corroborates findings of patients feeling uniformed and conflicted, we observed patients to experience significant emotional strain as they continued living in limbo while seeking information on their health and treatment.…”

Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy

“…Furthermore, most patients reported having several discussions about treatment options with their physician before a decision was made, and the physician’s recommendation and the information provided in those discussions may be highly influential on the patient’s decision. The importance of physician interactions in treatment decision-making was also recently shown for early-stage NSCLC patients when deciding about surgery and radiotherapy [ 19 ]. In a cross-sectional survey conducted after a decision was made, but before treatment, 85% of patients indicated that decision-making should ideally be shared between the patient and physician.…”

“…Additionally, physicians reported using MT among patient populations not included in NCCN guidelines for MT at the time of the survey. A recent survey of oncologists in the USA also reported that oncologists recommended lung cancer treatments outside of current recommended treatment strategies; approximately half of surveyed oncologists indicated that they would recommend chemotherapy for patients with advanced lung cancer with an ECOG PS of 3 (with no pain) [ 19 ].…”

Decisional conflict scale for elective thoracic surgery

“…Therefore, decisional conflict is expected to occur also in the surgical field [6]. However, the research targeted decision at surgery has been rarely performed.…”